Department of Clinical Biochemistry (Medical Genetics), Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.
Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Genes (Basel). 2022 Oct 31;13(11):1996. doi: 10.3390/genes13111996.
Long non-coding RNAs (lncRNAs) have key roles in tumor development and the progress of many cancers, including breast cancer (BC). This study aimed to explore for the first time the association of the migration/differentiation-associated lncRNA rs12420823C/T variant with BC risk and prognosis. Genotyping was carried out for 203 participants (110 patients and 93 controls) using the TaqMan allelic discrimination technique. The corresponding clinicopathological data, including the recurrence/survival times, were analyzed with the different genotypes. After adjustment by age and risk factors, the T/T genotype carrier patients were more likely to develop BC under homozygote comparison (T/T vs. C/C: OR = 8.33, 95% CI = 2.44-25.0, = 0.001), dominant (T/T-C/T vs. C/C: OR = 3.70, 95% CI = 1.72-8.33, = 0.027), and recessive (T/T vs. C/T-C/C: OR = 2.17, 95% CI = 1.08-4.55, < 0.001) models. Multivariate logistic regression analysis showed that the T/T genotype carriers were more likely to be triple-negative sub-type (OR = 2.66, 95% CI = 1.02-6.95, = 0.046), at a higher risk of recurrence (OR = 3.57, 95% CI = 1.33-9.59, = 0.012), and had short survival times (OR = 3.9, 95% CI = 1.52-10.05, = 0.005). Moreover, Cox regression analysis supported their twofold increased risk of recurrence (HR = 2.14, 95% CI = 1.27-3.59, = 0.004). Furthermore, the predictive nomogram confirmed the high weight for rs12420823T/T and C/T genotypes in predicting recurrence within the first year. The Kaplan-Meier survival curve demonstrated low disease-free survival (T/T: 12.5 ± 1.16 months and C/T: 15.9 ± 0.86 months versus C/C: 22.3 ± 0.61 months, < 0.001). In conclusion, the LncRNA SENCR rs12420823C/T may be associated with an increased risk of BC in women and could be a promising genetic variant for predicting recurrence and survival.
长链非编码 RNA（lncRNA）在肿瘤发生和许多癌症的进展中起着关键作用，包括乳腺癌（BC）。本研究旨在首次探讨迁移/分化相关 lncRNA rs12420823C/T 变异与 BC 风险和预后的关系。使用 TaqMan 等位基因鉴别技术对 203 名参与者（110 名患者和 93 名对照）进行基因分型。根据不同的基因型分析相应的临床病理数据，包括复发/生存时间。在年龄和危险因素调整后，与纯合子比较，T/T 基因型携带者更有可能发生 BC（T/T 与 C/C：OR = 8.33，95%CI = 2.44-25.0， = 0.001），显性（T/T-C/T 与 C/C：OR = 3.70，95%CI = 1.72-8.33， = 0.027）和隐性（T/T 与 C/T-C/C：OR = 2.17，95%CI = 1.08-4.55， < 0.001）模型。多变量逻辑回归分析显示，T/T 基因型携带者更有可能是三阴性亚型（OR = 2.66，95%CI = 1.02-6.95， = 0.046），复发风险更高（OR = 3.57，95%CI = 1.33-9.59， = 0.012），生存时间较短（OR = 3.9，95%CI = 1.52-10.05， = 0.005）。此外，Cox 回归分析支持他们复发风险增加两倍（HR = 2.14，95%CI = 1.27-3.59， = 0.004）。此外，预测列线图证实 rs12420823T/T 和 C/T 基因型在预测第一年复发方面具有较高的权重。Kaplan-Meier 生存曲线表明无病生存率较低（T/T：12.5 ± 1.16 个月和 C/T：15.9 ± 0.86 个月与 C/C：22.3 ± 0.61 个月， < 0.001）。总之，lncRNA SENCR rs12420823C/T 可能与女性 BC 风险增加相关，可能是预测复发和生存的有前途的遗传变异。
